Home/Stocks/AMRN

AMRN

USD

Amarin Corporation plc

$15.710+0.040 (0.255%)

Real-time Price

Healthcare

Drug Manufacturers - General

Ireland

Price Chart

Loading Chart...

Key Metrics

Market Metrics

Company Fundamentals

Trading Stats

Market Metrics

Open

$15.670

High

$15.745

Low

$15.110

Volume

0.06M

Company Fundamentals

Market Cap

326.7M

Industry

Drug Manufacturers - General

Country

Ireland

Trading Stats

Avg Volume

0.10M

Exchange

NCM

Currency

USD

52-Week Range

Low $7Current $15.710High $20.9

AI Analysis Report

Last updated: Nov 5, 2025

AI-GeneratedData Source: Yahoo Finance, Bloomberg, SEC

AMRN Analysis: Navigating Short-Term Volatility in Amarin Corporation Shares

Key Takeaways

Recent technical indicators show bullish momentum but conflicting signals
Q3 2025 results triggered sharp price drop, reflecting operational uncertainty
Stock trades at historical discount to 52-week highs but risks remain
Fundamental risks outweigh short-term value opportunities

Recent News Impact

Positive Developments

Scientific Validation (Nov 3, 2025) New analyses presented at AHA Scientific Sessions reinforce Vascepa’s clinical data consistency and mechanism of action.
FDA Labeling Support (Oct 27, 2025) Company publicly aligned with FDA’s fenofibrate labeling revision, potentially strengthening Vascepa’s competitive differentiation.

Mixed Earnings Release (Oct 29, 2025)

Q3 results highlighted international expansion progress but triggered a 10% single-day crash (from $18.50 to $16.70), suggesting market skepticism about execution risks in the new commercialization model.

Related News

Nov 3, 2025 · 01:30 PM

GlobeNewswire

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new

Oct 29, 2025 · 11:00 AM

GlobeNewswire

Amarin Reports Third Quarter 2025 Financial Results

Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand,

Oct 27, 2025 · 12:00 PM

GlobeNewswire

Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today issued the following statement

Oct 15, 2025 · 12:00 PM

GlobeNewswire

Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report

Oct 14, 2025 · 12:00 PM

GlobeNewswire

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian